chPD1-gdT

chPD1-gdT is an investigational **allogeneic gamma delta T-cell therapy** in which healthy donor-derived γδ T cells are genetically engineered to express a **chimeric programmed cell death protein 1 receptor**. The construct described in preclinical reporting uses the extracellular portion of PD-1 fused to the intracellular signaling domains of **DAP10** and **CD3 zeta**, with the goal of converting **PD-L1-mediated immune suppression into activating cytotoxic signaling** against **PD-L1-positive tumors**. The program has been reported in preclinical solid tumor models and was described as a planned Phase 1/2 candidate, but publicly available information is limited and no clearly established commercial brand name or confirmed manufacturer-specific asset profile was identified.

Brand names

Procel

Other names

gamma delta T cells engineered with a chimeric PD-1 receptorchimeric PD-1 gamma delta T cells